此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (C-couple)

2021年8月30日 更新者:Fei Gao、Sun Yat-sen University

Cryoablation Combined With Camrelizumab and Apatinib

The purpose of this study is to evaluate the efficacy and safety of cryoablation combined with pd-1 antibody immunotherapy (Camrelizumab) and anti-angiogenesis therapy (Apatinib) in patients with advanced hepatocellular carcinoma (HCC).

研究概览

地位

招聘中

条件

详细说明

This is a prospective, single arm, phase 2 study to evaluate the efficacy and safety of cryoablation combined with Camrelizumab and Apatinib (C-couple Therapy) in patients with advanced HCC. Subjects who meet the admission criteria will be treated with Camrelizumab and Apatinib after cryoablation until disease progression, intolerable toxicity, death, withdrawal of the patient or the researchers determined that the drug must be discontinued.

The primary outcome measure is to evaluate the objective response rate (ORR) of C-couple Therapy for advanced HCC (BCLC C-stage). The secondary outcome measures include the duration of response (DOR), disease control rate (DCR), progression-free survival rate (PFSR) in 6- and 12-months, overall survival rate (OSR) in 6- and 12-months, the median progression-free survival time (mPFS) and median overall survival time (mOS) of C-couple Therapy for advanced HCC. This study also aims to assess the safety and adverse reactions of C-couple Therapy for advanced HCC.

研究类型

介入性

注册 (预期的)

34

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • 招聘中
        • Sun Yat-sen University Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. The patient voluntarily joined the study and signed an informed consent form;
  2. ≥18 and ≤70 years old, both male and female;
  3. Clinically diagnosed or pathologically confirmed advanced hepatocellular carcinoma (unresectable or metastatic), at least one measurable focus without local treatment (according to mRECIST requirements, the measurable focus spiral CT scan length ≥ 10 mm or enlargement Short diameter of lymph node ≥15 mm);
  4. Child-Pugh score ≤ 6 points (Child-Pugh A);
  5. BCLC staging is stage C; PVTT classification is combined with PVTT (program classification PVTT ≤ 3), and a single lesion in the liver (or multiple lesions with diameter) ≤ 7cm of primary liver cancer.
  6. Newly diagnosed patients who have not received targeted therapy or immunotherapy in the past;
  7. Able to swallow pills normally;
  8. ECOG score: 0~1 (see Annex 1 for ECOG scoring criteria);
  9. Expected survival period ≥ 12 weeks;
  10. The functions of vital organs meet the following requirements (no blood components, cell growth factors and other corrective treatment drugs are allowed within 14 days before the first administration):

    The absolute count of neutrophils≥1.5×109/L; Platelet ≥80×109/L; Hemoglobin ≥90 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal, the levels of FT3 and FT4 should be examined at the same time, if the levels of FT3 and FT4 are normal, they can be included in the group); Bilirubin≤1.5×ULN (within 7 days before the first administration); ALT and AST ≤3×ULN (within 7 days before the first dose); AKP≤ 2.5×ULN; Serum creatinine≤1.5×ULN;

  11. Non-surgical sterilization or female patients of childbearing age need to use a medically approved contraceptive method (such as intrauterine device, contraceptive or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo surgical sterilization must be negative in serum or urine HCG within 72 hours before enrollment in the study; and must be non-lactating; for male patients whose partners are women of childbearing age, Carelil should be given during the trial and at the last time Use effective methods for contraception within 3 months after the onslumab.

Exclusion Criteria:

  1. The patient has any active autoimmune disease or a history of autoimmune disease;
  2. The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment;
  3. The number of system treatment lines ≥ 2 lines;
  4. Severe allergic reaction to other monoclonal antibodies;
  5. Those with a known history of central nervous system metastasis or hepatic encephalopathy;
  6. Patients whose liver tumor burden is greater than 50% of the total liver volume, or who have received liver transplantation in the past;
  7. Ascites with clinical symptoms, those who need puncture, drainage, or those who have received ascites drainage within the past 3 months, except those who have only a small amount of ascites on imaging but not accompanied by clinical symptoms;
  8. Suffer from high blood pressure and cannot be well controlled by antihypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
  9. Uncontrolled cardiac clinical symptoms or diseases, such as: NYHA level 2 or higher heart failure, unstable angina pectoris, myocardial infarction occurred within 1 year, clinically significant supraventricular or ventricular arrhythmia requires treatment or intervention , QTc>450ms (male); QTc>470ms (female);
  10. Abnormal coagulation function (INR>2.0, PT>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow the preventive use of low-dose aspirin and low molecular heparin;
  11. Significant clinically significant bleeding symptoms or clear bleeding tendency occurred within 3 months before randomization, such as pertussis/hemoptysis 2.5ml or more, gastrointestinal bleeding, esophageal and gastric varices with bleeding risk, hemorrhagic stomach Ulcer or vasculitis, etc., if the stool occult blood is positive at the baseline, it can be re-examined. If it is still positive after the re-examination, a gastroscopy is required. If the gastroscope shows severe esophageal and gastric varices, it cannot be included in the group (3 before the group) Except those who have undergone gastroscopy within a month or less to exclude such cases);
  12. Arterial/venous thrombosis events that occurred within 6 months before randomization, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
  13. Known genetic or acquired bleeding and thrombotic tendency (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, etc.);
  14. Urine routine test showed urine protein ≥ ++ and confirmed 24-hour urine protein content> 1.0 g;
  15. Patients who have previously received radiotherapy, chemotherapy, hormone therapy, and surgery, after the completion of the treatment (last medication) and less than 4 weeks before the study medication; molecular targeted therapy (including other oral targeted drugs used in clinical trials) is less than the first study medication <5 drug half-lives, or patients whose adverse events (except alopecia) caused by previous treatment have not recovered to ≤ CTCAE level 1;
  16. The patient has active infection, fever of unknown origin within 7 days before medication ≥38.5℃, or baseline white blood cell count >15×109/L;
  17. Patients with congenital or acquired immune deficiencies (such as HIV-infected persons);
  18. Patients with HBV DNA>2000 IU/ml (or 104 copies/ml), HCV RNA>103 copies/ml, HBsAg+ and anti-HCV antibody positive;
  19. The patient suffered from other malignant tumors in the past 3 years or at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ);
  20. Patients with bone metastases who received palliative radiotherapy within 4 weeks before participating in the study >5% of the bone marrow area;
  21. The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1, or has previously received apatinib therapy;
  22. Live vaccine may be vaccinated less than 4 weeks before study medication or may be administered during the study period;
  23. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, and serious laboratory tests Abnormalities, accompanied by family or social factors, will affect the safety of patients.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:C-couple
Camrelizumab and Apatinib after Cryoablation

Cryoablation

Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD

其他名称:
  • 冷冻消融

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
RECIST 1.1 和 mRECIST 的客观缓解率 (ORR)
大体时间:从研究药物首次给药之日起至疾病进展、出现不可接受的毒性、撤回同意或赞助终止(最长 2 年)
ORR 定义为根据 RECIST 1.1 和 mRECIST 评估,在数据截止时具有完全缓解 (CR) 或部分缓解 (PR) 的最佳总体缓解 (BOR) 的参与者百分比
从研究药物首次给药之日起至疾病进展、出现不可接受的毒性、撤回同意或赞助终止(最长 2 年)

次要结果测量

结果测量
措施说明
大体时间
疾病控制率(DCR)
大体时间:从研究药物首次给药之日起至疾病进展、疾病稳定、出现不可接受的毒性、撤回同意或赞助终止(最长 2 年)
DCR 定义为根据 RECIST 1.1 和 mRECIST 评估,在数据截止时具有完全缓解 (CR) 或部分缓解 (PR) 或稳定疾病 (SD) 的最佳总体缓解 (BOR) 的参与者百分比。
从研究药物首次给药之日起至疾病进展、疾病稳定、出现不可接受的毒性、撤回同意或赞助终止(最长 2 年)
RECIST 1.1 和 mRECIST 的反应持续时间 (DOR)
大体时间:从首次记录 CR 或 PR 到首次记录疾病进展或死亡,以先发生者为准(最多 2 年)
DOR 定义为根据 RECIST 1.1 和 mRECIST 评估,从首次记录 CR 或 PR 到首次记录疾病进展或死亡(以先发生者为准)的日期
从首次记录 CR 或 PR 到首次记录疾病进展或死亡,以先发生者为准(最多 2 年)
RECIST 1.1 和 mRECIST 的无进展生存率 (PFSR)
大体时间:从第一次服用研究药物的日期到第一次记录疾病进展或死亡的日期,以先发生者为准(最多 2 年)
6 个月和 12 个月的 PFSR
从第一次服用研究药物的日期到第一次记录疾病进展或死亡的日期,以先发生者为准(最多 2 年)
总生存率(OSR)
大体时间:从第一次服用研究药物的日期到第一次记录任何原因导致的死亡日期,以先发生者为准(最长 2 年)
6 个月和 12 个月内的 OSR
从第一次服用研究药物的日期到第一次记录任何原因导致的死亡日期,以先发生者为准(最长 2 年)
无进展生存时间 (mPFS)
大体时间:从第一次服用研究药物的日期到第一次记录疾病进展的日期(最长 2 年)
无进展生存时间 (mPFS) 定义为从第一个研究剂量日期到第一次记录疾病进展日期的时间,根据 RECIST 1.1 和 mRECIST 评估。
从第一次服用研究药物的日期到第一次记录疾病进展的日期(最长 2 年)
中位总生存时间 (mOS)
大体时间:从治疗阶段的开始日期到因任何原因死亡的日期(最多 2 年)
OS 是从治疗阶段的开始日期(第一次研究剂量的日期)到任何原因死亡的日期。 失访的参与者和在数据截止日期还活着的参与者将在最后一次知道参与者还活着的日期或截止日期(以较早者为准)进行审查。
从治疗阶段的开始日期到因任何原因死亡的日期(最多 2 年)

其他结果措施

结果测量
措施说明
大体时间
治疗相关不良事件
大体时间:从治疗阶段的开始日期到因任何原因死亡的日期(最多 2 年)
根据 CTCAE v4.0 评估的与治疗相关的不良事件的参与者人数。
从治疗阶段的开始日期到因任何原因死亡的日期(最多 2 年)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年9月1日

初级完成 (预期的)

2023年8月31日

研究完成 (预期的)

2024年8月31日

研究注册日期

首次提交

2021年1月25日

首先提交符合 QC 标准的

2021年1月25日

首次发布 (实际的)

2021年1月26日

研究记录更新

最后更新发布 (实际的)

2021年9月5日

上次提交的符合 QC 标准的更新

2021年8月30日

最后验证

2021年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅